ABSTRACT Objective To determine the prevalence and clinical characteristics of patients with “low‐positive” (LP) MOG‐IgG (titres 1:160–1:320) among adults with a first demyelinating event (FDE) suggestive of multiple sclerosis (MS). Methods From the Barcelona CIS inception cohort, we included adult patients with serum...
J. Villacieros-Álvarez, Carmen Espejo, G. Arrambide et al.· Annals of Clinical and Trans...· 0 citations
Failure to reduce zNfL levels after 1 year of treatment was associated with subsequent disease activity, even in patients otherwise considered stable, providing complementary information to clinical and MRI-based monitoring.
Victoria Fernández, A. Pappolla, P. Carbonell-Mirabent et al.· Neurology· 1 citation
Treatment de-escalation is sometimes necessary because of adverse effects, comorbidities, infections, treatment fatigue, or life circumstances such as pregnancy, but in pregnancy, management requires balancing maternal disease control with fetal safety, with strategies ranging from continuation of selected therapies to...
Y. Hacohen, G. Androdias, G. Arrambide et al.· Neurology· 0 citations
A review of current evidence on established and emerging fluid biomarkers in NMOSD and MOGAD, with emphasis on analytical performance, biological relevance, and clinical utility, and outlines priorities for future research.
S. Mariotto, Á. Cobo-Calvo, M. Khalil et al.· Neurology(R) neuroimmunology...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
